News stories about Keryx Biopharmaceuticals (NASDAQ:KERX) have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Keryx Biopharmaceuticals earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.1077423073743 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Watching the Tape Move for Keryx Biopharmaceuticals Inc (KERX) and Avista Corp (AVA) – Evergreen Caller (evergreencaller.com)
- Keryx Biopharmaceuticals, Inc. (KERX) Upgraded at BidaskClub (americanbankingnews.com)
- What the Technicals Say About Keryx Biopharmaceuticals, Inc. (KERX) – Economic News (economicsandmoney.com)
- Zacks: Analysts Anticipate Keryx Biopharmaceuticals, Inc. (KERX) Will Announce Quarterly Sales of $18.80 Million (americanbankingnews.com)
- Keryx Biopharmaceuticals, Inc. (KERX) Stake Held by Northeast Financial Consultants Inc (vothemes.com)
Keryx Biopharmaceuticals (NASDAQ KERX) traded down 3.12% during midday trading on Friday, hitting $6.52. The company’s stock had a trading volume of 968,998 shares. The company’s 50-day moving average is $7.22 and its 200 day moving average is $6.22. The company’s market cap is $774.25 million. Keryx Biopharmaceuticals has a one year low of $4.03 and a one year high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.60. The company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The firm’s revenue was up 62.4% on a year-over-year basis. During the same period last year, the business earned ($0.42) earnings per share. On average, analysts predict that Keryx Biopharmaceuticals will post ($1.23) EPS for the current year.
KERX has been the subject of several research analyst reports. Maxim Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Keryx Biopharmaceuticals in a report on Monday, May 1st. ValuEngine downgraded Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Cowen and Company reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday, June 17th. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research note on Wednesday, July 12th. Finally, BidaskClub downgraded Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $7.48.
COPYRIGHT VIOLATION NOTICE: This report was first published by Rincon Hill News and is the property of of Rincon Hill News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://rinconhillneighbors.org/2017/08/19/keryx-biopharmaceuticals-nasdaqkerx-receiving-somewhat-favorable-news-coverage-report-shows-updated-updated.html.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with our FREE daily email newsletter.